March 9, 2011

Ipsen, manufacturer of Dysport for Injection (also known in the US as abobotulinumtoxinA neurotoxin), is contacting physicians to conduct an observational registry stud. The goal of the registry, ANCHOR-CD, is to collect and evaluate typical treatment response information from cervical dystonia patients currently being treated with market-available Dysport.  The registry will recruit up to 400 cervical dystonia patients through physician practices across the US.  For more information please contact Sandra Russell, Senior Manager, Medical Affairs Neurology at 1.650.238.1672 or Sandra.russell@ipsen.com.